Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14463046 | 0.83 | GAA (0.38) | CYP3A4 | |
| SCHEMBL7633012 | 0.78 | MPO (0.54) | — | |
| SCHEMBL6113046 | 0.75 | CCNB2 (0.42) | ACHECYP3A4 | |
| SCHEMBL6112977 | 0.75 | MIF (0.48) | CA9 | |
| SCHEMBL6113173 | 0.74 | TUBB4A (0.44) | — | |
| SCHEMBL14462890 | 0.74 | L3MBTL1 (0.37) | — | |
| SCHEMBL4133075 | 0.72 | ATM (0.42) | — | |
| SCHEMBL6112766 | 0.71 | CCNB2 (0.47) | ACHECYP3A4 | |
| SCHEMBL28209834 | 0.71 | PDE10A (0.47) | MAOAACHE | |
| SCHEMBL6113150 | 0.70 | CCNB2 (0.40) | ACHECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263763-B1 | TUBULIN BINDING LIGANDS | UNIV BAYLOR (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1263763-B1 | TUBULIN BINDING LIGANDS | UNIV BAYLOR (US) | 2007-07-25 | — | — | EP | disclosed |
| US-6593374-B2 | Such as 3-(3'4'5'-trimethoxybenzoyl)-2-(3'benzylphosphate 4'methoxyphenyl)-6-methoxybenzo(b)thiophene; functionalized to prepare phosphate esters, phosphate salts, and phosphoramidates useful as antitumor agents | BAYLOR UNIVERSITY | 2003-07-15 | — | — | US | disclosed |
| EP-1263763-A2 | TUBULIN BINDING LIGANDS AND CORRESPONDING PRODRUG CONSTRUCTS | BAYLOR UNIVERSITY (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020055643-A1 | Tubulin binding ligands and corresponding prodrug constructs | MATEON THERAPEUTICS, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2001068654-A2 | TUBULIN BINDING LIGANDS AND CORRESPONDING PRODRUG CONSTRUCTS | BAYLOR UNIVERSITY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055643-A1 | Tubulin binding ligands and corresponding prodrug constructs | TUBB, TUBB3, TUBB4A | MAOA 2990/4885CA2 1918/4885CA9 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.